10/18/2024

Janusmed sex and gender

Janusmed sex and gender – Olaparib

Janusmed Sex and Gender is a knowledge database providing information on sex and gender aspects of drug treatment. The knowledge database is primarily intended to be used by physicians and healthcare professionals. The texts are general and should not be considered as treatment guidelines. The individual patient’s physician is responsible for the patient’s drug treatment.

Back to index
A A
A A

Olaparib

Olaparib

Class : A

Show all info

Print

Contact us

  1. Physicians' Desk Reference. http://www.pdr.net. [cited 2018-12-06].

  2. Fass.se [cited 2018-12-06].

  3. Karzai F, VanderWeele D, Madan RA, Owens H, Cordes LM, Hankin A et al. Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations. J Immunother Cancer. 2018;6(1):141.

  4. Clarke N, Wiechno P, Alekseev B, Sala N, Jones R, Kocak I et al. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2018;19(7):975-986.

  5. Martin GA, Chen AH, Parikh K. A Novel Use of Olaparib for the Treatment of Metastatic Castration-Recurrent Prostate Cancer. Pharmacotherapy. 2017;37(11):1406-1414.

  6. Gina Columbus. FDA Grants Olaparib Orphan Drug Designation for Pancreatic Cancer. OncLive [www]. [cited 2018-12-06].

  7. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2017 [cited 2018-12-06.]

  1. Physicians' Desk Reference. http://www.pdr.net. [cited 2018-12-06].
  2. Fass.se [cited 2018-12-06].
  3. Karzai F, VanderWeele D, Madan RA, Owens H, Cordes LM, Hankin A et al. Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations. J Immunother Cancer. 2018;6(1):141.
  4. Clarke N, Wiechno P, Alekseev B, Sala N, Jones R, Kocak I et al. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2018;19(7):975-986.
  5. Martin GA, Chen AH, Parikh K. A Novel Use of Olaparib for the Treatment of Metastatic Castration-Recurrent Prostate Cancer. Pharmacotherapy. 2017;37(11):1406-1414.
  6. Gina Columbus. FDA Grants Olaparib Orphan Drug Designation for Pancreatic Cancer. OncLive [www]. [cited 2018-12-06].
  7. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2017 [cited 2018-12-06.]